Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organoid Drug Sensitivity-Guided Treatment in Refractory Tumors
NCT07906301Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Open-label trial in tumor, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 7 more (9 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Objective Response Rate up to 24 months. Started Oct 2025; status: recruiting.
02
Conditions
tumornon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)prostate cancer (PCa)retroperitoneal leiomyosarcoma (RLMS)
Beyond the preview
Go deeper on NCT07906301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906301.